The EP-score to assess treatment efficacy in RRMS patients: a preliminary study

References

• Randomized double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352(9139):1498–504.
   PubMedGoogle Scholar
• Filippini G, Munari L, Incorvaia B, Interferons in relapsing remitting multiple sclerosis: A systematic review. Lancet. 2003;361(9357):545–52.
   PubMed Web of Science ®Google Scholar
• Shirani A, Zhao Y, Karim ME, Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247–56.
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Olee-Burkey MA, Lage MJ. Glatiramer Acetate and Interferon beta-1b: A study of outcomes among patients with multiple sclerosis. Adv Ther 2009; 26(5):552–62.
   PubMed Web of Science ®Google Scholar
• Edan G, Kappos L, Montalbán X, for the BENEFIT Study Group. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 2013 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Derfuss T, Kappos L. Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA 2012 Jul18;308(3):290–1.
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: A retrospective US claims database analysis. Curr Med Res Opin 2013 Dec;29(12):1647–56.
   PubMed Web of Science ®Google Scholar
• Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: A critique. Neurology 1988;38(11):1793–98.
   PubMed Web of Science ®Google Scholar
• Fernandez O, Fernandez V. Evoked potentials are of little use in the diagnosis or monitoring of MS: No. Mult Scler 2013 Dec;19(14):1822–3.
   PubMed Web of Science ®Google Scholar
• Jung P, Beyerle A, Ziemann U. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis. Mult Scler 2008;14:553–6.
   PubMedGoogle Scholar
• Kallmann BA, Fackelmann S, Toyka KV, Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 2006;12:58–65.
   PubMed Web of Science ®Google Scholar
• Leocani L, Rovaris M, Boneschi FM, Multimodal evoked potentials to assess the evolution of multiple sclerosis: A longitudinal study. J Neurol Neurosurg Psychiatry 2006;77(9):1030–5.
   PubMed Web of Science ®Google Scholar
• Margaritella N, Mendozzi L, Garegnani M, Sensory evoked potentials to predict short term progression of disability in multiple sclerosis. Neurol Sci 2012, Aug;33(4):887–92.
   PubMed Web of Science ®Google Scholar
• Margaritella N, Mendozzi L, Garegnani M, Exploring the predictive value of the evoked potentials score in MS within an appropriate dataset: A hint for an early identification of benign MS? BMC Neurol 2012 Aug 22;12:80.
   PubMed Web of Science ®Google Scholar
• Margaritella N, Mendozzi L, Tronci F, The evoked potentials score improves the identification of benign MS without cognitive impairment. Eur J Neurol. 2013 Oct;20(10): 1423–5.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Lenton K, Burke T The utility of multimodal evoked potentials in multiple sclerosis prognostication. J Clin Neurosci 2013 Nov;20(11):1576–81.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1):121–7.
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13(3):227–31.
   PubMed Web of Science ®Google Scholar
• Schlaeger R, D'Souza M, Schindler C Prediction of MS disability by multimodal evoked potentials: Investigation during relapse or in the relapse-free interval? Clin Neurophysiol 2014. (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Rodriguez-Mena D, Herrero R, Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS. Neurology 2013 Jul 2;81(1): 76–83.
   PubMed Web of Science ®Google Scholar
• Ko KF. The role of evoked potential and MR imaging in assessing multiple sclerosis: A comparative study. Singapore Med J 2010 Sep;51(9):716–20.
   PubMed Web of Science ®Google Scholar
• Schlaeger R, D'Souza M, Schindler C, Prediction of long-term disability in multiple sclerosis. Mult Scler 2012 Jan;18(1):31–8.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Baier M, Stockton R, et al. Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Mult Scler 2003 Oct;9(5): 529–34.
   PubMed Web of Science ®Google Scholar
• Niklas A, Sebraoui H, Hess E, Outcome measures for trials of remyelinating agents in multiple sclerosis: Retrospective longitudinal analysis of visual evoked potential latency. Mult Scler 2009 Jan;15(1):68–74.
   PubMed Web of Science ®Google Scholar
• Liscić RM, Brecelj J. Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a. Croat Med J 2004 Jun;45(3):323–7.
   PubMed Web of Science ®Google Scholar
• Anlar O, Kisli M, Tombul T, Visual evoked potentials in multiple sclerosis before and after two years of interferon therapy. Int J Neurosci 2003 Apr;113(4):483–9.
   PubMed Web of Science ®Google Scholar
• Fromont A, Debouverie M, Le Teuff G, Clinical parameters to predict response to Interferon in relapsing multiple sclerosis. Neuroepidemiology 2008;31:150–6.
   PubMed Web of Science ®Google Scholar